Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy

被引:12
作者
Bang, Lia E.
Wiinberg, Niels
Wachtell, Kristian
Larsen, John
Olsen, Michael H.
Tuxen, Christian
Hildebrandt, Per R.
Ibsen, Hans
机构
[1] Naestved Hosp, Naestved, Denmark
[2] Frederiksberg Univ Hosp, Frederiksberg, Denmark
[3] Rigshosp, DK-2100 Copenhagen, Denmark
[4] Glostrup Univ Hosp, Glostrup, Denmark
关键词
ambulatory blood pressure; hypertension; outcomes;
D O I
10.1080/08037050701642808
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objective. The Losartan Intervention For Endpoint reduction in hypertension ( LIFE) study showed that losartan-based treatment reduced risk of the composite endpoint of cardiovascular death, stroke and myocardial infarction compared with atenolol-based treatment in patients with hypertension and left ventricular hypertrophy with similar office blood pressure ( BP) reduction. Our aim was to investigate the effect of losartan-and atenolol-based treatment on 24-h ambulatory BP and heart rate (HR) in LIFE. Methods: In 110 patients, 24-h ambulatory BP and heart rate were recorded at baseline and 1 year after randomization. Results: Ambulatory BP was comparably reduced throughout the 24-h period after 1 year of losartan-vs atenolol-based antihypertensive treatment. Office and ambulatory BP were comparably reduced in the follow-up period. Early morning surge in BP was similar between groups. Non-dipping status was more frequent in the losartan group (p50.01). From baseline to Year 1 the 24-h HR profile for the losartan group was unchanged, but, as expected, there was a significant decrease in daytime HR in the atenolol group, which was not as large during early night-time. Conclusion: There were no differences in 24-h BP burden and HR that could explain the difference in outcome in favor of losartan vs atenolol in the LIFE study.
引用
收藏
页码:392 / 397
页数:6
相关论文
共 21 条
[1]  
Dahlof B, 1997, AM J HYPERTENS, V10, P705
[2]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[3]   Characteristics of 9194 patients with left ventricular hypertrophy -: The LIFE study [J].
Dahlöf, B ;
Devereux, RB ;
Julius, S ;
Kjeldsen, SE ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Hedner, T ;
Ibsen, H ;
Kristianson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
HYPERTENSION, 1998, 32 (06) :989-997
[4]   Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol -: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial [J].
Devereux, RB ;
Dahlöf, B ;
Gerdts, E ;
Boman, K ;
Nieminen, MS ;
Papademetriou, V ;
Rokkedal, J ;
Harris, KE ;
Edelman, JM ;
Wachtell, K .
CIRCULATION, 2004, 110 (11) :1456-1462
[5]   Circadian variation in blood pressure - Implications for the elderly patient [J].
Elliott, WJ .
AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (02) :43S-49S
[6]   Elevated systolic blood pressure and risk of cardiovascular and renal disease: Overview of evidence from observational epidemiologic studies and randomized controlled trials [J].
He, J ;
Whelton, PK .
AMERICAN HEART JOURNAL, 1999, 138 (03) :S211-S219
[7]  
HJALMARSON A, 1998, CLIN CARDIOL S2, V21, P3
[8]  
HOEGHOLM A, 1995, J HUM HYPERTENS, V9, P611
[9]   THE ACCURACY AND PERFORMANCE OF THE A-AND-D TM 2421, A NEW AMBULATORY BLOOD-PRESSURE MONITORING DEVICE BASED ON THE CUFF-OSCILLOMETRIC METHOD AND THE KOROTKOFF SOUND TECHNIQUE [J].
IMAI, Y ;
SASAKI, S ;
MINAMI, N ;
MUNAKATA, M ;
HASHIMOTO, J ;
SAKUMA, H ;
SAKUMA, M ;
WATANABE, N ;
IMAI, K ;
SEKINO, H ;
ABE, K .
AMERICAN JOURNAL OF HYPERTENSION, 1992, 5 (10) :719-726
[10]   Resting heart rate as a predictive risk factor for sudden death in middle-aged men [J].
Jouven, X ;
Zureik, M ;
Desnos, M ;
Guérot, C ;
Ducimetière, P .
CARDIOVASCULAR RESEARCH, 2001, 50 (02) :373-378